MNMD
Definium Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$20.69
+0.44%Price chart
Jul 14Jul 17Jul 22Jul 27Jul 30Aug 4Aug 7Aug 12
Key dataAug 12, 2026
Open$47.51
From 52W high−57.30%
Volume7.63M
Market cap$1.85B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataAug 12, 2026
Open
$47.51
From 52W high
−57.30%
Volume
7.63M
Market cap
$1.85B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−8.2x
P/E (TTM)
—
RSI (14)
50.9
MomentumView details →
1D Return
+0.44%
YTD Return
+219.57%
SummaryUpdated Jun 1, 2026
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Vancouver, Canada. The company went public in 2016 and focuses on developing novel therapeutic treatments for brain health disorders including psychiatry, addiction, pain, and neurology. MindMed is at the forefront of psychedelic medicine research, developing treatments based on compounds like LSD and MDMA that have shown promise in addressing mental health conditions that affect millions of people worldwide.
Similar companies
Latest newsMore news →
Celcuity Inc. appointed David W. Gryska as a director effective October 1, 2026, with an annual base salary of $70,000 and a pro-rated grant of 893 restricted stock units.18d agoDefinium Therapeutics issued inducement stock option grants to fifteen newly hired non-executive employees covering an aggregate of 334,810 common shares.21d agoThe U.S. Food and Drug Administration held a public hearing on September 14 on how psychedelic drugs might be used as supervised treatments, with public comments open until October 5.35d ago